Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review.
Christina M HuangMark G KirchhofPublished in: Journal of cutaneous medicine and surgery (2020)
Imiquimod showed clinical and histological clearance rates of over 70% for nBCC, with a recurrence rate of 1.80%. Although clearance rates are lower than surgery, IMQ can be considered as a treatment option for nBCC in those who decline or are unfit for surgical intervention.